PTSD Medications: Benefits, Risks, and Treatment Decisions
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Medications can reduce the symptoms of posttraumatic stress disorder (PTSD), particularly persistent intrusive memories, avoidance, heightened threat responses, and associated mood symptoms. For adults seeking medication, the best-supported choices are sertraline, paroxetine, and venlafaxine. Sertraline and paroxetine are FDA-approved for PTSD in the United States; venlafaxine has strong guideline support for PTSD but is prescribed off-label for this indication. These recommendations come from the 2023 VA/DoD clinical practice guideline and its National Center for PTSD clinician's guide.
The decision to take medication depends on a clinical assessment, the benefits that matter to the individual, previous treatment experiences, other health conditions, pregnancy considerations, potential interactions, access to psychotherapy, and willingness to monitor adverse effects. Evidence-based trauma-focused psychotherapy is generally preferred when it is accessible and acceptable. Medication remains a legitimate evidence-based treatment choice, especially when psychotherapy is unavailable, unsuitable at present, or not the person's preference.
This guide examines what PTSD medications can accomplish, the evidence for each major drug group, differences among guidelines, safety and monitoring, and how people and clinicians can make and revise treatment decisions.
I. What Are PTSD Medications?
PTSD medications are prescription drugs used to reduce symptoms of a clinically assessed posttraumatic stress disorder. Most recommended medicines are antidepressants that act on serotonin, or serotonin and norepinephrine, signaling systems. Their clinical usefulness is established through controlled treatment trials; an individual's PTSD does not have to be explained by a simple chemical imbalance for these medications to help.
PTSD can involve intrusive recollections or nightmares, avoidance of reminders, persistent perceptions of threat, changes in mood and beliefs, distress, and impaired functioning. The precise diagnostic criteria differ between DSM-5-TR and ICD-11. Both frameworks require more than exposure to an upsetting event or a high score on a questionnaire. A clinical assessment also considers depression, anxiety disorders, substance use, sleep disorders, medication effects, physical conditions, dissociation, and safety.
A drug prescribed for depression, insomnia, panic symptoms, pain, or a co-occurring illness may be clinically appropriate for that condition while having limited evidence for the PTSD syndrome itself. Throughout this article, “recommended for PTSD” means a recommendation supported by PTSD-specific evidence, rather than an implication that every medicine used by a person with PTSD treats PTSD.
II. Which Medications Are Recommended for PTSD?
1. Sertraline: an FDA-approved SSRI
Sertraline (Zoloft) is a selective serotonin reuptake inhibitor (SSRI) with moderate-certainty PTSD-specific evidence in the VA/DoD framework and an FDA-approved PTSD indication. It is one of the principal medication options for adults. Potential benefits include reduced intrusive symptoms, avoidance, hyperarousal, and related depressive or anxiety symptoms, although improvement varies across people and symptom domains. The VA patient decision aid explains expected benefits and treatment monitoring.
Common adverse effects include nausea, diarrhea, headache, changes in sleep, sweating, and sexual difficulties. Early agitation or worsening insomnia may require reassessment rather than automatic dose escalation. Like other serotonergic antidepressants, sertraline also has rare but serious risks and interactions. Its National Library of Medicine drug monograph documents precautions, warning signs, and interactions.
2. Paroxetine: another FDA-approved SSRI
Paroxetine (Paxil) also has an FDA-approved PTSD indication and moderate-certainty evidence supporting symptom improvement. It may be considered when its expected benefits fit the person's clinical history, tolerability, and preference. There is no reliable individual-level test that identifies paroxetine as the best choice for every patient.
Paroxetine can cause nausea, sweating, fatigue, sexual dysfunction, and other SSRI adverse effects. It is particularly important to discuss discontinuation symptoms if doses are missed or treatment ends, because paroxetine is associated with a greater withdrawal burden than some alternatives. Pregnancy planning deserves an individualized medication review rather than automatic continuation, switching, or discontinuation. See the National Library of Medicine paroxetine monograph.
3. Venlafaxine: a strongly recommended SNRI prescribed off-label
Venlafaxine (Effexor XR) is a serotonin–norepinephrine reuptake inhibitor (SNRI). The 2023 VA/DoD guideline strongly recommends it for adult PTSD on the basis of moderate-certainty evidence, even though it does not have an FDA-approved PTSD indication. Off-label prescribing means the specific indication is outside FDA labeling; it does not mean the treatment has no research support.
Venlafaxine can cause nausea, sweating, sleep changes, sexual side effects, and discontinuation symptoms. Blood pressure monitoring is particularly important because venlafaxine can raise blood pressure in some patients. A missed-dose or abrupt-stopping pattern may produce dizziness, sensory disturbances, nausea, irritability, or other withdrawal symptoms. The National Library of Medicine venlafaxine monograph describes these precautions.
4. How the three main options compare
The strongest guideline-supported PTSD medications do not have a reliably established ranking for every patient. Choice often turns on previous individual response, adverse effects, drug interactions, pregnancy or breastfeeding plans, blood pressure, sleep, coexisting depression, cost, treatment availability, and the practical difficulty of taking a medication consistently. A clinician may reasonably prefer one SSRI or an SNRI for a particular person without claiming that it is universally superior.
The National Center for PTSD describes these three medications as broadly comparable choices. The drugs may take several weeks to show meaningful benefit, and the clinical response should be evaluated over an adequate monitored trial rather than after just a few doses.
III. What Does the Research Actually Show?
The most relevant recent synthesis is the 2026 Cochrane systematic review by Williams and colleagues, which included 66 randomized controlled trials involving 7,442 adults and pooled 54 studies in meta-analysis. In studies contributing to its primary SSRI treatment-response outcome, approximately 58% of participants receiving SSRIs improved compared with 35% receiving placebo. The review graded the SSRI evidence as moderate certainty. These are group-level trial results, not an estimate of any particular patient's likelihood of recovery.
The same review found more discontinuations attributed to adverse effects among people receiving SSRIs than placebo. The absolute proportion discontinuing an SSRI because of adverse events was approximately 9% in the trials analyzed for that outcome. Single small trials suggested potential benefits for mirtazapine and amitriptyline, but those findings were low-certainty and do not establish either as a preferred PTSD medication.
These studies have important limits. Trials differed in how PTSD was diagnosed, trauma exposure, participant demographics, symptom severity, previous treatment, permitted co-treatments, drug choice, outcome definition, and follow-up. Many drug trials were comparatively short. Differences in populations and measurements prevent a simple prediction about long-term recovery, relapse after stopping, or response in adolescents, pregnant patients, older adults, and people with complex comorbidity. Improvements in group averages also do not imply that every symptom is equally medication-responsive.
A separate 2025 systematic review and meta-analysis reported improvement with pharmacotherapy across a heterogeneous collection of trials, while emphasizing individual variation and discontinuation. Its pooled proportions from diverse agents and trial designs should not be read as a direct head-to-head ranking of different medications.
IV. How Do Major PTSD Treatment Guidelines Differ?
1. VA/DoD: psychotherapy preferred, three medications strongly recommended
The 2023 VA/DoD guideline favors specific trauma-focused psychotherapies over pharmacotherapy when available and aligned with a patient's preferences. Among medications, it gives a strong positive recommendation to paroxetine, sertraline, and venlafaxine. It also recommends against benzodiazepines and cannabis or cannabis derivatives for PTSD. The recommendation strength reflects both evidence and the benefit–harm assessment, rather than a claim that medication works identically for everyone.
2. American Psychological Association: evidence-based treatments and different grading
The American Psychological Association's PTSD guideline and its medications treatment material list fluoxetine alongside paroxetine, sertraline, and venlafaxine in medication discussions. The APA treatment materials use conditional recommendations for several drugs, reflecting their evidence assessment and recommendation process. Readers should distinguish an association's suggested or conditional treatment option from U.S. FDA approval and from the VA/DoD's more selective strong-medication list.
The presence of fluoxetine in APA material and its placement in VA/DoD's insufficient-evidence category are differences in guidance, not proof that one source overlooked the medicine. For clinical decisions, the underlying studies, quality judgments, safety considerations, and current prescribing context must be assessed.
3. NICE: medication when an adult prefers drug treatment
The United Kingdom's NICE guideline NG116 recommends considering venlafaxine or an SSRI such as sertraline for adults diagnosed with PTSD who prefer medication, with regular review. NICE generally gives priority to trauma-focused psychological interventions. It advises against medication to prevent PTSD after trauma and against drug treatment for prevention or treatment of PTSD in people younger than 18.
4. WHO: psychological interventions and age-sensitive decisions
The World Health Organization's guidance for adults supports psychological interventions including trauma-focused CBT and EMDR. WHO's earlier stress-related conditions recommendations discourage antidepressants as the initial choice for adult PTSD when appropriate psychological care is available and advise against antidepressants specifically to manage PTSD in children and adolescents. Guidance dates, populations, and evidence-grading methods should be considered when comparing these documents.
V. Medications for PTSD Nightmares and Sleep Problems
1. Prazosin has a specific, narrower role
Prazosin is an alpha-1 adrenergic blocker originally used for hypertension. The VA/DoD guideline suggests it for nightmares associated with PTSD, but suggests against using it to treat the overall PTSD syndrome. This distinction is fundamental: an improvement in recurring nightmares is a separate outcome from broad improvement in intrusion, avoidance, threat perception, and everyday functioning.
The evidence is mixed. Some smaller studies and pooled analyses suggest improvement in nightmares, while a large 2018 multicenter placebo-controlled trial by Raskind and colleagues did not show an advantage on its main sleep and PTSD outcomes among military veterans studied. Differences in sample selection and the outcomes measured help explain continuing clinical uncertainty; no drug is guaranteed to eliminate nightmares.
Prazosin can lower blood pressure and cause dizziness, lightheadedness, falls, or fainting, particularly when starting or increasing treatment or when combined with other blood-pressure-lowering medicines. Review the National Library of Medicine's prazosin safety information. The choice, dose, and monitoring belong with a prescriber.
2. Other sleep medications require a separate question
Insomnia, obstructive sleep apnea, restless legs, substance-related sleep disruption, and medication-induced sleep problems may coexist with PTSD. Treating one of these conditions can be appropriate even when the drug involved is not established as a treatment for PTSD itself. Sedating antidepressants, antihistamines, hypnotics, and antipsychotics differ substantially in benefit and risk; sedation alone does not demonstrate treatment of posttraumatic stress.
For persistent insomnia, a clinician can consider behavioral sleep treatment and evaluate the underlying sleep disorder. For nightmares, the relative place of prazosin, nightmare-focused psychological treatment, and general PTSD treatment depends on the individual's presentation. A future EN-04 article will examine prazosin specifically; this article preserves the larger medication-treatment decision.
VI. Medications With Limited, Conflicting, or Unfavorable PTSD Evidence
1. Fluoxetine and other antidepressants
Fluoxetine has been evaluated for PTSD and appears in APA treatment material, but VA/DoD 2023 concludes that the evidence is insufficient for a positive or negative PTSD-specific recommendation. The same VA/DoD category includes several agents that may be useful for other diagnosed conditions, including escitalopram, citalopram, duloxetine, desvenlafaxine, mirtazapine, bupropion, and others. “Insufficient evidence” is a statement about confidence in PTSD-specific benefit and harm, not a universal prohibition on prescribing any of these drugs.
The 2026 Cochrane review found only low-certainty positive signals for mirtazapine and amitriptyline from small studies. Those signals support further research and individualized specialist assessment. They do not justify treating all antidepressants as equivalent or presenting a medication selected for sleep or depression as proven therapy for PTSD.
2. Benzodiazepines: an important recommendation against routine PTSD treatment
Benzodiazepines such as alprazolam, lorazepam, and clonazepam may reduce acute anxiety or cause sedation. They have not demonstrated an adequate PTSD-specific benefit to justify their risks, and the VA/DoD guideline strongly recommends against them for PTSD treatment. Concerns include tolerance, dependence, withdrawal, impaired cognition, sedation, falls, and particular danger when combined with alcohol or opioids.
A person already taking a benzodiazepine should discuss any change with the prescribing clinician. Abrupt discontinuation after regular use can cause serious withdrawal, including seizures. The guideline against using a drug for PTSD is not an instruction to stop an existing prescription suddenly.
3. Antipsychotics: risks and narrow specialist circumstances
Risperidone has unfavorable PTSD-specific evidence, including a large randomized trial of adjunctive risperidone for persistent military-related PTSD symptoms that did not establish clinically meaningful overall benefit. See Krystal and colleagues' trial. The VA/DoD guideline suggests against several atypical antipsychotics as medication augmentation in PTSD because the evidence of added benefit is inadequate and harms can be substantial.
Risks can include weight gain, metabolic changes, diabetes, abnormal movements, and cardiac or sedative effects. NICE allows carefully monitored specialist consideration of an antipsychotic alongside psychological treatment in selected adults with disabling symptoms after other treatments have failed. This narrower exception should be understood in its clinical context rather than generalized to routine prescribing.
4. Mood stabilizers, anticonvulsants, and other candidates
Divalproex, guanfacine, tiagabine, vortioxetine, and ketamine are among medicines the 2023 VA/DoD guideline suggests against for treating the overall PTSD syndrome. Evidence for many other drugs remains insufficient. Prescribing a drug for an independent condition such as bipolar disorder, epilepsy, or neuropathic pain is a different clinical decision from prescribing it for PTSD.
5. Cannabis, psychedelics, and experimental treatments
VA/DoD recommends against cannabis or cannabis-derived products as a PTSD treatment because a convincing benefit has not been established and relevant harms exist. Its 2023 guideline judged evidence insufficient for a recommendation for or against MDMA-assisted psychotherapy and several other psychedelic approaches. Research findings and investigational protocols should be distinguished from standard treatment, clinical authorization, and individual safety.
Ketamine-based and other novel strategies continue to be studied, but emerging interest does not establish long-term effectiveness or an acceptable benefit–harm profile for routine PTSD prescribing. Regulatory status and local legal rules can change; any claim about present authorization must be checked for the specific product and country.
VII. Benefits, Side Effects, and Serious Safety Risks
1. What benefits can medication offer?
A meaningful response can involve fewer intrusive memories, less avoidance and hyperarousal, reduced depressive symptoms, improved sleep or concentration, greater day-to-day functioning, and more ability to engage in relationships, work, or psychological treatment. The relevant outcome is the individual's sustained change in symptoms and functioning, weighed against side effects and treatment burden. A reduction in a questionnaire score alone is incomplete evidence of meaningful recovery.
2. Common adverse effects and individual trade-offs
SSRIs and SNRIs may cause gastrointestinal upset, headache, sweating, appetite changes, insomnia or sleepiness, agitation, and sexual difficulties. Some effects fade; others persist and affect adherence, relationships, or quality of life. Paroxetine and venlafaxine merit particular planning around missed doses and discontinuation symptoms. Venlafaxine may require blood pressure checks. Discussing potential side effects before treatment helps establish what the person would consider acceptable.
3. Serious risks that need timely attention
Antidepressants carry warnings about increased suicidal thinking or behavior in children, adolescents, and young adults, particularly early in treatment or around dose changes. Any new suicidal thinking, intense agitation, marked behavioral change, or severe deterioration requires prompt clinical evaluation. The sertraline, paroxetine, and venlafaxine monographs describe these warnings.
Other uncommon but potentially serious problems include serotonin syndrome, abnormal bleeding, low sodium in vulnerable patients, and medication-triggered mania in a person susceptible to bipolar disorder. Review interactions with other prescription medicines, supplements, alcohol, and recreational substances. Fever with confusion, marked muscle rigidity, or severe autonomic symptoms may require emergency assessment. New episodes of unusually elevated or irritable mood with greatly reduced need for sleep warrant urgent clinician contact.
4. Pregnancy, breastfeeding, aging, and medical conditions
Medication planning during pregnancy or breastfeeding requires individualized assessment of maternal illness severity, benefits of treatment, fetal or infant exposure, previously effective treatment, and the risks of abrupt discontinuation. Paroxetine warrants particular reproductive safety review. In older adults, falls, sodium abnormalities, polypharmacy, cognition, and cardiovascular health may become more important. Liver or kidney disease, seizures, glaucoma risk, hypertension, and anticoagulant use can also change the calculation.
These questions require the person's actual health and medication history. A generalized list of “safe” or “unsafe” PTSD medicines cannot replace an individual perinatal, psychiatric, or medical evaluation.
VIII. How to Start and Monitor PTSD Medication
1. Confirm the clinical target
The first task is establishing whether the person meets criteria for PTSD, has another mental health condition, has both, or is experiencing a post-event response without PTSD. A prescriber assesses symptoms, exposure and timing, distress, functioning, psychiatric history, physical health, existing medications, substance use, and safety. Screening questionnaires can help quantify symptom severity and track change but do not establish a diagnosis on their own.
2. Agree on meaningful treatment goals
Before choosing a drug, identify the problems that matter most: recurrent intrusive experiences, persistent fear, avoidance, depression, insomnia, nightmares, social functioning, or the ability to engage in therapy. A realistic goal includes potential benefits, expected delays, adverse effects the individual wishes to avoid, and what would count as adequate improvement.
3. Allow an adequate monitored trial
SSRIs and SNRIs generally require regular use over several weeks before benefits can be assessed. Dose selection and changes are individualized, and people should not adjust doses based on an online article. Early follow-up is particularly important when there is suicidality risk, activation, intolerable adverse effects, or complex medication interaction potential. Clinical reviews evaluate symptoms, function, adherence, adverse events, and whether the diagnosis or treatment approach needs reconsideration.
4. What if the first medication does not work?
A disappointing initial trial can reflect insufficient duration, adherence difficulty, dose limitations, side effects, incorrect diagnostic formulation, untreated co-occurring conditions, or genuine nonresponse despite an adequate trial. The next step is a structured reassessment. Options may include changing the medication under supervision, prioritizing a trauma-focused psychotherapy, addressing nightmares or insomnia separately, or consulting a specialist when symptoms remain severe or clinically complex.
There is insufficient robust PTSD-specific evidence to assume that adding more medication to an SSRI or combining an SSRI with psychotherapy always improves outcomes over a suitable single evidence-based treatment. This uncertainty concerns average additional efficacy; individualized concurrent treatment may still be clinically reasonable, especially when a separate condition also needs care. The VA National Center for PTSD review sets out these combination-evidence limitations.
5. How long should treatment continue?
Continuation depends on the response, severity, side effects, clinical course, recurrence risk, preferences, and the prescriber's judgment. Evidence is stronger for short-term symptom reduction than for one universal treatment duration or a fixed relapse-prevention schedule. Improvement is a reason to review the plan, not to abruptly stop medication.
Antidepressant discontinuation should be planned with the prescriber; gradual tapering may reduce withdrawal symptoms, and the pace varies by drug and person. Symptoms after a change may reflect withdrawal, recurrence, another medical problem, or some combination and should be evaluated rather than automatically interpreted as PTSD relapse.
IX. Medication or Trauma-Focused Psychotherapy?
Prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing (EMDR) have strong PTSD-specific psychotherapy evidence and are preferred in the VA/DoD framework. These approaches address trauma-linked memory, fear, meaning, avoidance, and functioning through structured clinical methods. Their purposes differ from those of daily pharmacotherapy, and evidence from one treatment cannot simply be transferred to another.
Medication may be appropriate when someone prefers it, has limited access to trained psychotherapy, needs treatment for co-occurring depression, or makes an informed choice after reviewing benefits and risks. For many patients, a prescriber and therapist can coordinate care when both are involved. However, combining treatments is not automatically more effective, and the question of incremental benefit is distinct from whether each intervention is independently evidence-based.
For a broad comparison of PTSD-specific clinical treatments, see PTSD Treatment: Evidence-Based Therapy and Medication Options. For a broader view of recovery and functioning, see Trauma Recovery: Rebuilding Safety and Function After Trauma.
X. Special Clinical Situations
1. Children and adolescents
Medication evidence in pediatric PTSD is substantially weaker than the adult evidence base. NICE recommends against offering drug treatment specifically to prevent or treat PTSD in people under 18. Trauma-focused child and adolescent psychological care is the primary recommended approach. A child may nevertheless receive medication for a separately established condition under an appropriately qualified clinician's care. The existence of an adult PTSD medication indication should not be interpreted as pediatric authorization.
2. Complex PTSD and dissociation
ICD-11 complex PTSD includes PTSD symptoms together with enduring disturbances in self-organization. The evidence for medication as a specific treatment for complex PTSD is limited; trials of standard PTSD pharmacotherapy do not automatically establish effects on all additional CPTSD domains. Dissociative symptoms may complicate assessment and treatment planning, but a dissociative PTSD subtype is distinct from independent dissociative disorders. Clinical decisions require a careful formulation of actual symptoms and co-occurring conditions.
3. Depression, substance use, and suicide risk
Depression may coexist with PTSD and may affect drug choice and treatment sequencing. Substance use can influence medication safety, interactions, withdrawal, adherence, and clinical monitoring. NICE advises against excluding a person from PTSD care solely because substance misuse coexists. If there is immediate risk of suicide, serious self-harm, or dangerous loss of behavioral control, urgent safety assessment and appropriate emergency care take priority over routine medication selection. For immediate danger, contact local emergency services.
4. After a recent traumatic event
An acute stress response, acute stress disorder, and established PTSD are different clinical states. Medication evidence for treating diagnosed PTSD should not be used to justify routine preventive prescribing after every traumatic event. NICE explicitly recommends against drug treatment, including benzodiazepines, to prevent PTSD. Early clinical support and evidence-based psychological intervention should be evaluated according to symptoms, timing, risks, and the person's needs.
XI. A Shared Decision-Making Checklist
Before starting or changing a prescription, discuss the confirmed diagnosis, the specific symptoms and functioning the medicine is intended to improve, the strength of PTSD-specific evidence for the proposed medication, its FDA approval or off-label status, and available trauma-focused treatment options.
Ask about likely adverse effects, sleep and sexual health concerns, suicidal thinking or bipolar symptoms, blood pressure or other monitoring, interactions with all other medicines and supplements, pregnancy or breastfeeding plans, missed-dose instructions, costs, follow-up timing, and what to do if the treatment is ineffective. Record the treatment goals and agree on a review point with the clinician.
The VA PTSD Treatment Decision Aid provides a structured way to compare psychotherapy and medication options. Collaborative decisions are strongest when the person understands both expected benefit and uncertainty, and the clinician has sufficient information to evaluate safety.
XII. Frequently Asked Questions
What is the best medication for PTSD?
For adult PTSD, the most consistently and strongly recommended medications in the 2023 VA/DoD guideline are sertraline, paroxetine, and venlafaxine. The choice among them depends on individual clinical factors and tolerability. There is no medication established as the single best option for every person.
Are there any FDA-approved medications specifically for PTSD?
Yes. Sertraline and paroxetine are FDA-approved in the United States for PTSD. Venlafaxine has strong PTSD-specific guideline support but is used off-label for this diagnosis. FDA approval and evidence-based off-label use are separate concepts.
Does medication cure PTSD?
Medication can significantly reduce symptoms for some people, but trial evidence does not establish a permanent cure from taking a drug. Outcomes vary, and ongoing treatment or reassessment may be useful. Sustained recovery is evaluated through functioning, distress, symptom patterns, and individual priorities.
How long do PTSD medications take to work?
Improvement commonly develops over several weeks rather than immediately. An appropriate evaluation depends on adherence, dose, tolerability, baseline symptoms, and a clinician's follow-up. A few days without benefit is usually too early to conclude that an SSRI or SNRI has failed.
Which medication helps PTSD nightmares?
Prazosin may be considered for PTSD-associated nightmares, with a qualified clinician assessing low blood pressure, dizziness, falls, and other medications. Its evidence is mixed, and it is not recommended as a general treatment for all PTSD symptoms.
Why are benzodiazepines generally discouraged for PTSD?
They have not shown a convincing benefit for core PTSD symptoms, while dependence, withdrawal, cognitive impairment, sedation, falls, and interactions can create substantial harm. People already taking one should seek a supervised plan rather than stopping abruptly.
Can PTSD medication be taken with therapy?
Yes, medications and psychotherapy may be used together when clinically appropriate, including for co-occurring disorders. The additional PTSD-specific benefit of routine combination treatment over an adequate single treatment is not firmly established. Decisions should be individualized and coordinated.
Is fluoxetine recommended for PTSD?
Fluoxetine appears in APA PTSD medication material, but the 2023 VA/DoD guideline finds insufficient evidence for a recommendation for or against its PTSD-specific use. A clinician should consider the actual evidence, medical history, and alternative treatments rather than treating all SSRIs as identical.
Can someone with PTSD take medication while pregnant?
The decision requires individualized assessment of the benefits and risks of continuing, initiating, or changing a prescription, together with untreated-symptom risks and obstetric or psychiatric guidance. Pregnancy planning is especially important when paroxetine is involved. Do not abruptly stop a medicine without clinical advice.
Are antidepressants recommended for children with PTSD?
Guidelines prioritize trauma-focused psychological treatment in children and adolescents. NICE recommends against medication specifically for PTSD treatment or prevention in people under 18 because supporting evidence is inadequate. Other independently diagnosed conditions require separate assessment.
What should I do if I feel worse after starting medication?
Contact the prescriber promptly, particularly if there is intense agitation, new suicidal thinking, mania-like changes, or significant side effects. Severe symptoms, immediate danger, or suspected serotonin syndrome require urgent medical assessment. Dose changes should be clinician-directed.
Do medication side effects always mean treatment should stop?
No. The clinical response depends on the type, severity, and duration of the adverse effect, potential interactions, and available alternatives. Some effects lessen; others call for a medication adjustment or change. A supervised discussion is safer than skipping or abruptly stopping a prescribed antidepressant.
Related Articles
PTSD Treatment: Evidence-Based Therapy and Medication Options — the broader treatment decision, psychotherapy evidence, and medication's place in care.
PTSD Screening vs Diagnosis: How Assessment Works — why structured clinical assessment matters before choosing treatment.
Trauma Recovery: Rebuilding Safety and Function After Trauma — recovery goals extending beyond symptom-score improvement.
PTSD vs Complex PTSD: How the Diagnoses Differ — understanding ICD-11 complex PTSD and limits of transferring evidence across diagnoses.
References
American Psychological Association. (2025). Clinical practice guideline for the treatment of posttraumatic stress disorder in adults. Official guideline.
American Psychological Association. (2025). Medications for PTSD. Treatment material.
Jia, Y., Ye, Z., Yang, F., et al. (2025). Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 15, 20451253251342628. https://doi.org/10.1177/20451253251342628
Krystal, J. H., Rosenheck, R. A., Cramer, J. A., et al. (2011). Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial. JAMA, 306(5), 493–502. https://doi.org/10.1001/jama.2011.1080.
National Institute for Health and Care Excellence. (2018, current NG116). Post-traumatic stress disorder: Recommendations. https://www.nice.org.uk/guidance/ng116/chapter/recommendations.
National Library of Medicine. Paroxetine. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a698032.html.
National Library of Medicine. Prazosin. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a682245.html.
National Library of Medicine. Sertraline. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a697048.html.
National Library of Medicine. Venlafaxine. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a694020.html.
Raskind, M. A., Peskind, E. R., Chow, B., et al. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine, 378, 507–517. https://doi.org/10.1056/NEJMoa1507598.
U.S. Department of Veterans Affairs and U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/.
U.S. Department of Veterans Affairs, National Center for PTSD. Clinician's guide to medications for PTSD. https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp.
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. C. (2026). Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews, 2026(5), CD002795. https://doi.org/10.1002/14651858.CD002795.pub4.
World Health Organization. (2013). Guidelines for the management of conditions specifically related to stress. NCBI Bookshelf official publication.
World Health Organization. (2023 updated recommendations). Posttraumatic stress disorder (PTSD): Psychological interventions — adults. Official guidance.